172 related articles for article (PubMed ID: 38880926)
1. [Progress and Discussion of Perioperative Targeted Therapy in Patients
with EGFR-mutated Resectable Non-small Cell Lung Cancer].
Song P; Cui Y
Zhongguo Fei Ai Za Zhi; 2024 May; 27(5):383-390. PubMed ID: 38880926
[TBL] [Abstract][Full Text] [Related]
2. A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer.
Cheng H; Li XJ; Wang XJ; Chen ZW; Wang RQ; Zhong HC; Wu TC; Cao QD
Lung Cancer; 2019 Nov; 137():7-13. PubMed ID: 31520922
[TBL] [Abstract][Full Text] [Related]
3. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
4. [Advances of Molecular Targeted Therapy in EGFR-mutated Squamous Cell Lung Cancer].
Xiong B; Ke W; Jiang W
Zhongguo Fei Ai Za Zhi; 2024 Apr; 27(4):283-290. PubMed ID: 38769831
[TBL] [Abstract][Full Text] [Related]
5. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
6. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
Zhao Y; Wang H; He C
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758
[TBL] [Abstract][Full Text] [Related]
7. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.
Chen YM
J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257
[TBL] [Abstract][Full Text] [Related]
8. Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Wen M; Wang L; Wang X; Yang S; Sun Y; Xia J; Zhang Y; Zhang Z; Huang L; Jiang T
Oncol Res Treat; 2020; 43(12):686-693. PubMed ID: 33197924
[TBL] [Abstract][Full Text] [Related]
9. [Research Progress of Targeted Therapy for EGFR Gene in Non-small Cell Lung Cancer].
Zhang H; Zhang S
Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):61-65. PubMed ID: 28103975
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.
Raphael J; Vincent M; Boldt G; Shah PS; Rodrigues G; Blanchette P
Am J Clin Oncol; 2019 May; 42(5):440-445. PubMed ID: 30913091
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of adjuvant EGFR inhibitors and impact of clinical factors in resected
Li M; Hou X; Lin S; Zheng L; Liang J; Chen J; Wang N; Zhang B; Chen L
Future Oncol; 2022 Mar; 18(9):1159-1169. PubMed ID: 35109665
[TBL] [Abstract][Full Text] [Related]
13. Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer.
Inoue A
Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(7):266-272. PubMed ID: 32788550
[TBL] [Abstract][Full Text] [Related]
14. The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation.
Sgambato A; Casaluce F; Maione P; Rossi A; Rossi E; Napolitano A; Palazzolo G; Bareschino MA; Schettino C; Sacco PC; Ciadiello F; Gridelli C
Curr Med Chem; 2012; 19(20):3337-52. PubMed ID: 22664249
[TBL] [Abstract][Full Text] [Related]
15. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
16. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
[TBL] [Abstract][Full Text] [Related]
17. [Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer].
Zhou W; Zhang W; Han B
Zhongguo Fei Ai Za Zhi; 2020 Feb; 23(2):118-126. PubMed ID: 32093456
[TBL] [Abstract][Full Text] [Related]
18. Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?
Tartarone A; Lerose R; Lazzari C; Gregorc V; Aieta M
Med Oncol; 2014 Aug; 31(8):78. PubMed ID: 24958518
[TBL] [Abstract][Full Text] [Related]
19. Is there a role for first generation TKIs in adjuvant setting of EGFR mutated early NSCLC?
Ospina AV; Provencio M
Chin Clin Oncol; 2023 Jun; 12(3):30. PubMed ID: 37303222
[No Abstract] [Full Text] [Related]
20. [Treatment progress for EGFR wild-type advanced non-small cell lung cancer].
Ma F; Shi X; Meng W; Zhang J; Zhao L; He X; Zhao J
Zhongguo Fei Ai Za Zhi; 2014 Jul; 17(7):575-80. PubMed ID: 25034590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]